News & Articles

FEATURED ARTICLE

MASP2 Antibody Successful in Phase III Clinical Trial

On December 19, 2024, Omeros announced that its pivotal Phase 3 clinical trial of the MASP2 antibody Narsoplimab (OMS721) in the treatment of TA-TMA (Transplant-Associated Thrombotic Microangiopathy) met its primary endpoint of overall survival (OS), with a 3-fold reduction in mortality risk [1]. Omeros stock surged 37% after the press release...

Browse articles by topic:

Have questions? Get in touch!

support@kactusbio.us